Chemokine receptor expression in Hodgkin disease
| Entity . | Case no. . | Proportion of positive tumor cells . | ||
|---|---|---|---|---|
| CCR7 . | CXCR4 . | CXCR5 . | ||
| HD-MC | 1 | +++ | ++ | (+) |
| HD-MC | 2 | +++ | +++ | NA |
| HD-MC | 3 | +++ | ++ | Negative |
| HD-MC | 4 | ++ | NA | NA |
| HD-MC | 5 | ++ | E | Negative |
| HD-MC | 6 | + | +++ | (+) |
| HD-MC | 7 | (+) | +++ | NA |
| HD-MC | 8 | + | +++ | (+) |
| HD-MC | 9 | (+) | ++ | Negative |
| HD-MC | 10 | E | +++ | NA |
| HD-MC | 11 | NA | E | E |
| HD-NS | 12 | +++ | +++ | ++ |
| HD-NS | 13 | +++ | +++ | NA |
| HD-NS | 14 | +++ | + | +++ |
| HD-NS | 15 | +++ | ++ | ++ |
| HD-NS | 16 | +++ | NA | NA |
| HD-NS | 17 | +++ | +++ | ++ |
| HD-NS | 18 | +++ | +++ | ++ |
| HD-NS | 19 | ++ | +++ | +++ |
| HD-NS | 20 | ++ | ++ | ++ |
| HD-NS | 21 | ++ | +++ | (+) |
| HD-NS | 22 | + | ++ | ++ |
| HD-NS | 23 | + | +++ | NA |
| HD-NS | 24 | + | (+) | (+) |
| HD-NS | 25 | + | + | NA |
| HD-NS | 26 | + | +++ | (+) |
| HD-NS | 27 | + | +++ | ++ |
| HD-NS | 28 | (+) | (+) | ++ |
| HD-NS | 29 | (+) | ++ | (+) |
| HD-NLP | 30 | (+) | ++ | + |
| HD-NLP | 31 | Negative | Negative | NA |
| HD-NLP | 32 | Negative | + | ? |
| HD-NLP | 33 | Negative | Negative | ++ |
| HD-NLP | 34 | Negative | + | + |
| HD-NLP | 35 | Negative | ++ | NA |
| HD-NLP | 36 | Negative | ++ | NA |
| Entity . | Case no. . | Proportion of positive tumor cells . | ||
|---|---|---|---|---|
| CCR7 . | CXCR4 . | CXCR5 . | ||
| HD-MC | 1 | +++ | ++ | (+) |
| HD-MC | 2 | +++ | +++ | NA |
| HD-MC | 3 | +++ | ++ | Negative |
| HD-MC | 4 | ++ | NA | NA |
| HD-MC | 5 | ++ | E | Negative |
| HD-MC | 6 | + | +++ | (+) |
| HD-MC | 7 | (+) | +++ | NA |
| HD-MC | 8 | + | +++ | (+) |
| HD-MC | 9 | (+) | ++ | Negative |
| HD-MC | 10 | E | +++ | NA |
| HD-MC | 11 | NA | E | E |
| HD-NS | 12 | +++ | +++ | ++ |
| HD-NS | 13 | +++ | +++ | NA |
| HD-NS | 14 | +++ | + | +++ |
| HD-NS | 15 | +++ | ++ | ++ |
| HD-NS | 16 | +++ | NA | NA |
| HD-NS | 17 | +++ | +++ | ++ |
| HD-NS | 18 | +++ | +++ | ++ |
| HD-NS | 19 | ++ | +++ | +++ |
| HD-NS | 20 | ++ | ++ | ++ |
| HD-NS | 21 | ++ | +++ | (+) |
| HD-NS | 22 | + | ++ | ++ |
| HD-NS | 23 | + | +++ | NA |
| HD-NS | 24 | + | (+) | (+) |
| HD-NS | 25 | + | + | NA |
| HD-NS | 26 | + | +++ | (+) |
| HD-NS | 27 | + | +++ | ++ |
| HD-NS | 28 | (+) | (+) | ++ |
| HD-NS | 29 | (+) | ++ | (+) |
| HD-NLP | 30 | (+) | ++ | + |
| HD-NLP | 31 | Negative | Negative | NA |
| HD-NLP | 32 | Negative | + | ? |
| HD-NLP | 33 | Negative | Negative | ++ |
| HD-NLP | 34 | Negative | + | + |
| HD-NLP | 35 | Negative | ++ | NA |
| HD-NLP | 36 | Negative | ++ | NA |
HD indicates Hodgkin disease; MC, mixed cellularity; NS, nodular sclerosis; NLP, nodular lymphocyte-predominant; +++, 50% to 100% positive tumor cells; ++, 20% to 50% positive tumor cells; +, 10% to 20% positive tumor cells; (+), less than 10% positive tumor cells; E, single positive tumor cells; NA, not analyzed.